JP2025516358A5 - - Google Patents
Info
- Publication number
- JP2025516358A5 JP2025516358A5 JP2024565272A JP2024565272A JP2025516358A5 JP 2025516358 A5 JP2025516358 A5 JP 2025516358A5 JP 2024565272 A JP2024565272 A JP 2024565272A JP 2024565272 A JP2024565272 A JP 2024565272A JP 2025516358 A5 JP2025516358 A5 JP 2025516358A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- group
- alkyl
- cancer
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339262P | 2022-05-06 | 2022-05-06 | |
| US63/339,262 | 2022-05-06 | ||
| US202263398769P | 2022-08-17 | 2022-08-17 | |
| US63/398,769 | 2022-08-17 | ||
| US202263429814P | 2022-12-02 | 2022-12-02 | |
| US63/429,814 | 2022-12-02 | ||
| US202363454477P | 2023-03-24 | 2023-03-24 | |
| US63/454,477 | 2023-03-24 | ||
| PCT/US2023/020987 WO2023215471A1 (en) | 2022-05-06 | 2023-05-04 | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516358A JP2025516358A (ja) | 2025-05-27 |
| JP2025516358A5 true JP2025516358A5 (enExample) | 2026-05-01 |
Family
ID=86760567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565272A Pending JP2025516358A (ja) | 2022-05-06 | 2023-05-04 | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250282771A1 (enExample) |
| EP (1) | EP4519260A1 (enExample) |
| JP (1) | JP2025516358A (enExample) |
| AU (1) | AU2023265886A1 (enExample) |
| CA (1) | CA3256666A1 (enExample) |
| MX (1) | MX2024013311A (enExample) |
| WO (1) | WO2023215471A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260111020A (ko) * | 2023-11-07 | 2026-07-14 | 트리라인 바이오사이언시스, 인크. | 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제 |
| AU2024378690A1 (en) * | 2023-11-07 | 2026-05-07 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| IL327973A (en) * | 2023-11-07 | 2026-06-01 | Treeline Biosciences Inc | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| WO2020163823A2 (en) | 2019-02-08 | 2020-08-13 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| AU2020310147A1 (en) | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| CN112707900B (zh) | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CA3163593A1 (en) | 2020-01-15 | 2021-07-22 | Guangrong Zheng | Therapeutic agents and methods of treatment |
| CA3173843A1 (en) | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| WO2023044046A1 (en) | 2021-09-17 | 2023-03-23 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
-
2023
- 2023-05-04 EP EP23730236.9A patent/EP4519260A1/en active Pending
- 2023-05-04 US US18/859,011 patent/US20250282771A1/en active Pending
- 2023-05-04 CA CA3256666A patent/CA3256666A1/en active Pending
- 2023-05-04 JP JP2024565272A patent/JP2025516358A/ja active Pending
- 2023-05-04 WO PCT/US2023/020987 patent/WO2023215471A1/en not_active Ceased
- 2023-05-04 AU AU2023265886A patent/AU2023265886A1/en active Pending
-
2024
- 2024-10-28 MX MX2024013311A patent/MX2024013311A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025517642A5 (enExample) | ||
| JP2025516359A5 (enExample) | ||
| JP7326622B2 (ja) | Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用 | |
| JP2021063119A (ja) | 噴霧乾燥製剤 | |
| JP6547042B2 (ja) | 非選択的キナーゼ阻害剤 | |
| WO2021197499A1 (zh) | 八氢吡嗪并二氮杂萘啶二酮类化生物 | |
| JP2024026074A (ja) | Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療 | |
| WO2021204111A1 (zh) | 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物 | |
| JP2019163324A (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2003523381A (ja) | 投与レジメン | |
| CN112105618B (zh) | 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 | |
| JP2003525252A (ja) | Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| CN103214484A (zh) | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 | |
| CN1313094C (zh) | Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途 | |
| CN1886389B (zh) | 喹喔啉化合物 | |
| JP2024500181A (ja) | 繊維芽細胞活性化タンパク質阻害剤 | |
| WO2020259626A1 (zh) | 作为irak4抑制剂的咪唑并吡啶类化合物 | |
| JP2025516543A5 (enExample) | ||
| JP2009533472A (ja) | 癌治療法 | |
| JP2022502438A (ja) | Ｆｇｆｒ４阻害剤及びその使用 | |
| JP2022517110A5 (enExample) | ||
| CN101616584A (zh) | 前列环素衍生物 | |
| WO2024093681A1 (zh) | 英菲格拉替尼在治疗胃癌和腺癌中的用途 | |
| WO1996032101A1 (en) | Cancerous metastasis inhibitor |